Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, October 6, 2026

Back to today

From X

@KEDM_COM

KEDM.com on X

ProQR Therapeutics $PRQR CEO Daniel de Boer bought $513K across two separate purchases on July 7 and July 9, and a company director bought another $229.5K in late June (real money for a Dutch CEO). PRQR is a small-cap RNA-editing biotech backed by a major pharma partner: Eli Lilly. Their collaboration, running since 2021 and expanded in 2022, could pay ProQR up to $3.75 billion in milestones plus royalties, real validation for a company this size. The balance sheet just got stronger too: ProQR raised roughly $59 million in late June 2026, with Lilly buying in alongside the public offering to keep its stake intact, a vote of confidence from the partner who knows their science best.
@pennycheck

⚽️📡 on X

I really think this can be a meaningful catalyst for Blacksky Aside from it opening a new vertical and revenue stream, as well as a entirely new TAM. The social arbitrage when every retail investor realizes how cool this tech is and the company behind the imagery and the AI read through on what the images says can be extreme. It is rolling out at first 4 observation sets related to 24 companies but obviously that is only the beginning. I believe this can be the start of a broader inflection of blackskys role in the mega theme i've been discussing the past few months of the value of proprietary data to increase exponentially over the coming months and years as advanced AI capabilities make the value and ease of monetization of proprietary data extremely valueable which also leads into how $BKSY edge in gen-3 having 35cm over the 50cm of competitors planet and satellogic become all the more valuable as AI tools. Many of these data 'moat' stocks have begun to re-rate in the past few months and I think this release on robinhood could be the start of that inflection in the sat names with blacksky leading the way to the social arb aspect of being integrated into hood as mentioned earier. $BKSY is also starting to become a massive beneficiary of the sovereign space infra spend which i've discussed and highlighted before with a now robust pipeline on sovereign deals through 27' as they discussed on the call. They also have moonshot upside working with the Air Force on orbital data centers. Shorts have begun to cover but still have a looooong way to go 20% is still short and as you probably know I am not a big TA guy but even i can spot a triple bottom I think it's a decent risk/reward assuming mkt can hold up a bit here

Investor Letters

All letters

Not So Fast

Entravision, the portfolio’s largest position, fell more than 40% from its highs as Q3 returns dropped to 37.8% YTD.

EVC $634M
The Mikro Kap 1 click

Zentek Research Note

Zentek shipped its first ZenGUARD air-filter order to a Canadian federal facility as its Albany graphite PEA confirmed a US$3.85 billion…

ZTEKF $58M
Atrium Research - Equity Research 1 click

💥Yield!💥

Beyond Meat’s Q2 2026 revenue fell 8.2% as U.S. retail and foodservice volumes declined, while a flatter, not inverted, Treasury curve…

BYND $132M
PETITION

Updates

FGPR remains on track, PRTH's management buyout is set at $8.05, and microcap RAVE is described as cheap.

FGPR $248MPRTH $644M
Nat Stewart - Stock Picking Newsletter 8 clicks

Is The Bond Market Running On Empty?

U.S. Treasury yields are testing credit and equity markets, while the discussion also targets recent changes at Glass House (GLAS).

GLAS $401M
WHAT ARE WE DOING? “Contrarians At The Gate” 1 click
TOYO · short

Toyo CO LTD

TOYO CO LTD is the target of a short thesis.

TOYO $185M
Value Investors Club

ALTO- ALTO ingredients

ALTO Ingredients trades near half of book value after plant upgrades and lower corn prices set up a recovery in crush margins and cash flow.

ALTO $289M
Sylence Capital 1 click

Notes and Updates

ECIP recipient banks could repurchase Treasury preferred shares at steep discounts, potentially lifting book value, while Hawaiian Electric…

UBAB $186M
Exploring with Alluvial Capital

Mereo Biopharma

Mereo Biopharma has two late-stage assets, seeks non-dilutive financing for alvelestat Phase 3 trials, and reports cash runway through 2027.

MREO $56M
Raging Bull Investments

JBG Smith

JBG Smith trades at an estimated 40% discount to NAV, backed by National Landing multifamily assets, Amazon HQ demand and $1.3 billion of…

JBGS $813M
Raging Bull Investments

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 46 of 218

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.